MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Status:
Terminated
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25
mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12
months in patients with relapsing-remitting MS